Potassium Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials by Filippini, T. et al.
Journal of the American Heart Association
J Am Heart Assoc. 2020;9:e015719. DOI: 10.1161/JAHA.119.015719 1
 
SYSTEMATIC REVIEW AND META-ANALYSIS
Potassium Intake and Blood Pressure: 
A Dose- Response Meta- Analysis of 
Randomized Controlled Trials
Tommaso Filippini, MD; Androniki Naska, PhD; Maria-Iosifina Kasdagli, MSc; Duarte Torres, PhD;  
Carla Lopes, PhD; Catarina Carvalho, MSc; Pedro Moreira, PhD; Marcella Malavolti, BSc, PhD; Nicola Orsini, PhD;  
Paul K. Whelton, MB, MD, MSc; Marco Vinceti, MD, PhD
BACKGROUND: Epidemiologic studies, including trials, suggest an association between potassium intake and blood pressure 
(BP). However, the strength and shape of this relationship is uncertain.
METHODS AND RESULTS: We performed a meta- analysis to explore the dose- response relationship between potassium supple-
mentation and BP in randomized- controlled trials with a duration ≥4 weeks using the recently developed 1- stage cubic spline 
regression model. This model allows use of trials with at least 2 exposure categories. We identified 32 eligible trials. Most were 
conducted in adults with hypertension using a crossover design and potassium supplementation doses that ranged from 
30 to 140 mmol/d. We observed a U- shaped relationship between 24- hour active and control arm differences in potassium 
excretion and BP levels, with weakening of the BP reduction effect above differences of 30 mmol/d and a BP increase above 
differences ≈80 mmol/d. Achieved potassium excretion analysis also identified a U- shaped relationship. The BP- lowering ef-
fects of potassium supplementation were stronger in participants with hypertension and at higher levels of sodium intake. The 
BP increase with high potassium excretion was noted in participants with antihypertensive drug- treated hypertension but not 
in their untreated counterparts.
CONCLUSIONS: We identified a nonlinear relationship between potassium intake and both systolic and diastolic BP, although 
estimates for BP effects of high potassium intakes should be interpreted with caution because of limited availability of trials. 
Our findings indicate an adequate intake of potassium is desirable to achieve a lower BP level but suggest excessive potas-
sium supplementation should be avoided, particularly in specific subgroups.
Key Words: blood pressure ■ dietary supplement ■ dose-response meta-analysis ■ potassium
Modification of dietary factors may affect the risk of cardiovascular diseases (CVDs).1–3 A primary mechanism of action is through lowering blood 
pressure (BP), the most important major modifiable risk 
factor for CVD.4–6 Both a lower sodium and a higher 
potassium intake have been associated with lowering 
of BP and a reduction in CVD.7–10 The role of these ele-
ments in BP control has been studied extensively in lab-
oratory and epidemiological studies.5,11–13 In particular, 
experimental human studies (ie, randomized controlled 
trials [RCTs]) suggest that potassium supplementation 
may decrease BP,14–17 particularly in adults with hyper-
tension.12 However, an accurate assessment of the po-
tassium- BP dose- response relationship has not been 
possible because of a lack of biostatistical models to 
conduct flexible, curvilinear modeling of RCTs with only 
2 levels of exposure (placebo and potassium supple-
mentation).12,18,19 This has also hampered the use of 
evidence on the BP effects of potassium in recent risk 
assessments of adequate potassium intake performed 
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by the European Food Safety Authority and the US 
National Academy of Medicine.13,19,20 These assess-
ments have therefore focused on outcomes, such as 
stroke21 and other CVD events,14,19 although this evi-
dence is limited by availability of only a relatively small 
number of studies that have used an observational 
design. In contrast, many RCTs have been conducted 
for estimation of the effect of potassium on BP. Some 
evidence has accrued from observational studies sug-
gesting that a high potassium intake may increase the 
risk of hypertension,22 stroke,21 and CVD mortality.23,24 
This has resulted in some concern about the potential 
for long- term adverse effects of a high potassium in-
take in the general population.23–29
In this review, we aimed to assess the dose- 
response relationship between potassium intake and 
BP on the basis of use of a new biostatistical method,30 
which allowed us to use experimental studies based 
on comparisons of 2 levels of potassium exposure, as 
is typical in most RCTs. In addition, we sought to com-
pare the results of our dose- response meta- analysis 
with corresponding assessments generated using 
conventional meta- analysis analytic techniques based 
on the assumption of a linear association between po-
tassium intake and BP.
METHODS
The authors declare that all supporting data are availa-
ble within the article and its online supplementary files.
Literature Search
We conducted a literature search for articles published 
on or before March 14, 2020, using the PubMed da-
tabase, with no language restriction. The research 
question was configured according to the Population, 
Exposure, Comparator(s), Outcomes, and Study 
Design statement and used the search terms “potas-
sium” and “blood pressure.”31 Details of the search 
strategy are provided in Table S1. Reference lists were 
screened to identify additional publications.
A study was considered eligible if: (1) it was per-
formed in participants with hypertension (apart from 
secondary hypertension) or without hypertension; (2) 
exposure to potassium was assessed through use of 
either dietary questionnaires or urinary measurements; 
(3) the outcome of interest was systolic BP (SBP), di-
astolic BP (DBP), or both; (4) an experimental design 
and a minimum intervention duration of 4 weeks had 
been used, to ensure biological effect of the interven-
tion, increase comparability with long- term habitual 
potassium intake, and provide consistently with recent 
systematic reviews14,18,19; (5) the intervention was per-
formed using potassium- containing supplements, and 
not through dietary modification only or by administra-
tion of mixed interventions with other active compo-
nents; and (6) measurements of urinary sodium and 
potassium excretion obtained before and after potas-
sium supplementation were available. The trial results 
were imported into Covidence systematic review soft-
ware (Veritas Health Innovation, Melbourne, Australia; 
http://www.covid ence.org) for further assessment and 
data extraction. At least 2 authors reviewed all titles 
and abstracts independently. If they disagreed, the 
final decision was reached by a majority decision with 
the help of a third author.
Risk of Bias Assessment
We conducted an independent assessment of study 
quality using the risk of bias (RoB) assessment tool 
(2.0). The following 6 RoB domains were considered: 
(1) randomization process errors; (2) deviations from 
the intended interventions; (3) missing outcome data; 
(4) systematic errors in measurement of the outcome; 
CLINICAL PERSPECTIVE
What Is New?
• Use of the new “1-stage” natural cubic spline 
model allowed, for the first time, pooling of ex-
perience in 2-arm randomized controlled trials 
to characterize the dose-response relation-
ship between potassium supplementation and 
blood pressure (BP).
• Results of this dose-response meta-analysis 
suggested a nonlinear relationship that included 
BP reduction but also indicated that both low 
and high potassium intake may result in an in-
creased level of BP, particularly but not exclu-
sively in participants with hypertension.
What Are the Clinical Implications?
• There seems to be a U-shaped relationship be-
tween potassium intake and BP, which might 
explain reports of deleterious cardiovascular 
disease outcomes at low and high intakes of po-
tassium, and suggests an optimal BP-lowering 
range for potassium intake.
Nonstandard Abbreviations and Acronyms
BP blood pressure
CVD cardiovascular disease
DBP diastolic blood pressure
RCT randomized controlled trial
RoB risk of bias
SBP systolic blood pressure
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(5) bias in selection of the reported result. In addition, 
we included an evaluation of the (6) RoB related to 
use of a crossover study design, assessing the use of 
a washout period and whether the trial duration was 
at least 4 weeks. Each domain could be character-
ized as having a low RoB, some concerns, or a high 
RoB. A study was assigned an overall higher RoB if 
it was judged to be at higher risk for at least 1 do-
main, and an intermediate RoB when some concern 
existed for at least 1 of domains 1, 2, and 6, or for ≥2 
domains 3 to 5.
Data Extraction
For each eligible study, the following data were ex-
tracted independently by 2 of the authors (M.I.K., 
T.F.) and confirmed by a third author (D.T.): first author 
name, publication year, country, duration of potas-
sium intervention phase, number of participants and 
their characteristics (sex, age, hypertensive status, use 
of antihypertensive medication), study design, pres-
ence and duration of a washout period, modality of 
BP measurement, type and quantity of the potassium 
supplements, baseline and achieved potassium excre-
tion level, sodium excretion at baseline and after the 
intervention, modification of sodium intake, and sum-
mary statistics of SBP and DBP levels (mean level in 
each group, active and control, for crossover studies 
or mean difference for parallel studies along with SD/
SE).
Statistical Analysis
We performed a meta- analysis of SBP and DBP 
weighted mean differences before and after potas-
sium supplementation for each study and for the rele-
vant subgroups using a “1- stage” natural cubic spline 
regression model on the basis of a random effects 
model,32 assessing heterogeneity with the I2 statis-
tic.33 The 1- stage method, consisting of a weighted 
mixed effects model, was recently developed30 and 
used in dose- response meta- analysis,34,35 and it al-
lowed us to make inferences about the average 
dose- response relationship between changes in po-
tassium excretion attributable to supplementation or 
overall potassium excretion at the end of the trial and 
changes in SBP and DBP levels. The 1- stage ap-
proach allowed us to include trials based on 2 levels 
of exposure, as was the case for most of the trials 
included in our study. Having no specific paramet-
ric assumptions about the shape of the association, 
we used restricted cubic splines of potassium with 
3 knots at fixed percentiles (10%, 50%, and 90%).36 
For comparison, we also used a linear function to 
model potassium intake in relationship to level of BP. 
Estimates of the parameters were obtained using re-
stricted maximum likelihood.30,36
We defined the mean difference in potassium ex-
cretion between the arms of each RCT as the differ-
ence between the values of potassium excretion at the 
end of the trial and the ones at baseline in each arm. 
Likewise, we defined the mean difference in BP follow-
ing the intervention as the difference for SBP and DBP 
at the end of the trial minus the corresponding baseline 
value.
In addition to the main analysis, we conducted 
stratified analyses based on study design (parallel 
versus crossover), hypertension status, use of anti-
hypertensive medication (excluding normotensives), 
baseline potassium excretion (<75 and ≥75 mmol/d), 
position during BP measurement (supine, seated, 
standing, or other), type of BP measurement device 
(automatic or manual), baseline sodium excretion (<3, 
3–4, or ≥4 g/d), and length of follow- up (≥12 weeks). In 
sensitivity analyses, we excluded trials at high risk for 
bias. We also reran the main analysis repeatedly, each 
time without one of the studies, to assess the missing 
study’s influence on overall mean BP change, and we 
assessed the study- specific dose- response trends in 
comparison with the corresponding dose- response 
meta- analysis for all trials.
Publication bias was examined using funnel plots. 
We used Stata statistical software (Stata Corp, 
College Station, TX, 2019) for our data analysis, in-
cluding the 1- stage approach based on the drmeta 
command.37
RESULTS
The Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses literature search flowchart is pre-
sented in Figure 1. We retrieved 236 unique study ar-
ticles, 144 of which were excluded on the basis of the 
article’s title or abstract. Main reasons for exclusion 
were: nonexperimental design (including case reports), 
experimental studies where the intervention did not in-
clude potassium supplementation or where potassium 
was included in a mixed intervention with other active 
components, secondary hypertension, and animal and 
in vitro studies. Following full- text review, we excluded 
60 of the remaining 92 articles because they were 
review articles, were reports based on a potassium 
supplementation phase <4 weeks, did not report on 
urinary excretion of potassium or sodium, did not pro-
vide BP levels, were not based on a potassium supple-
mentation trial, and were duplicate reports or detailed 
studies confined to children.
The Table presents main characteristics of the 32 
eligible trials in our meta- analysis.38–70 The trials were 
published between 1982 and 2016. They included 1764 
participants from Europe (N=17), America (N=7), Asia 
(N=4), Oceania (N=3), and Africa (N=1). All had been 
conducted in both sexes, with the exception of 2 that 
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were restricted to women and 1 to men. Participant 
age ranged from 18 to 79  years, with mean values 
between 24 and 75 years. Nine trials used a parallel 
design, whereas 23 were crossover studies, with 5 of 
the latter including a washout period of 1 to 5 weeks. 
Most (N=27) were conducted in participants with hy-
pertension, in 6 of which prior treatment with antihy-
pertensive medication (mainly ž blockers, thiazide, or 
calcium channel blockers) was continued during the 
trial, whereas 4 trials were restricted to participants 
without hypertension. BP was measured using an au-
tomatic device (n=15), a manual device (N=13), or both 
(N=4). Potassium was administered in the form of po-
tassium chloride (N=28), citrate (N=6), carbonate (N=2), 
aspartate (N=1), and/or glucoronate (N=1) at potassium 
doses that generally ranged from 30 to 120 mmol/d. All 
the trials had estimates of 24- hour potassium excretion 
in each study arm, both at baseline and at the end of 
the intervention. The achieved difference in potassium 
excretion at the end of the trial ranged from 17 to 
131 mmol/d.
RoB assessment results are presented in Table S2, 
with reference to both single- item evaluation and over-
all RoB. Overall, we judged only 2 of the trials as having 
a high RoB.43,56
In the dose- response meta- analysis assessing ef-
fects of changes in potassium excretion between the 
control and supplemented groups on BP changes 
within each trial (Figure 2), we found that mean SBP 
and DBP levels decreased in the supplemented group 
with increasing differences in potassium excretion, up 
to a value of ≈30 mmol/d. At higher levels of supple-
mentation, the decrease in BP was reduced, up to 
approximately a net difference in urinary potassium of 
80 mmol/d. More substantial net differences in urinary 
potassium between the supplemented and unsupple-
mented participants resulted in an increase in both SBP 
and DBP. Increases of 30, 60, 90, and 120 mmol/d in 
Figure 1. Flowchart of systematic literature search for trials published through March 14, 2020, that met the study inclusion 
and exclusion criteria.
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net urinary potassium excretion differences between 
the supplemented and unsupplemented participants 
resulted in SBP changes of −3.3 (95% CI, −4.9 to −1.6), 
−2.0 (95% CI, −3.4 to −0.5), 1.1 (95% CI, −2.9 to 4.7), 
and 4.2  (95% CI, −2.3 to 10.6) mm Hg, respectively. 
For DBP, the corresponding changes were −2.3 (95% 
CI, −3.8 to −0.7), −1.3 (95% CI, −2.8 to 0.1), 0.86 (95% 
CI, −2.9 to 4.6), and 3.1 (95% CI, −3.5 to 9.7) mm Hg, 
respectively.
When we superimposed the average predicted 
mean difference in BP estimated according to a linear 
function into the dose- response graph, it showed an 
inverse association between potassium supplementa-
tion and both SBP and DBP (Figure S1). A forest- plot 
meta- analysis comparing BP levels in the supple-
mented and referent groups identified a mean differ-
ence of −3.9 (95% CI, −5.2 to −2.6) and −2.4 (95% CI, 
−3.8 to −1.1) mm Hg for SBP and DBP, respectively 
(Figure S2).
Figure 3 presents the BP difference in our dose- 
response meta- analysis on the basis of achieved po-
tassium excretion at the end of the trial, using as a 
reference point a potassium excretion of 90 mmol/d 
(3500  mg/d). The SBP and DBP change remained 
constant in the range of 90 to 150 mmol/d of achieved 
potassium excretion. Below these ranges of achieved 
potassium excretion, the intervention effects on BP 
were unfavorable, and a weak BP increase also ap-
peared to occur at >150 mmol/d. A potassium excre-
tion of 30, 60, 120, 150, and 180 mmol/d resulted in 
SBP changes of 9.1 (95% CI, 4.6–13.5), 3.9 (95% CI, 
2.1–5.8), −0.9 (95% CI, −1.6 to −0.2), −0.2 (95% CI, 
−2.2 to 1.8), and 0.7 (95% CI, −2.9 to 4.2) mm Hg, re-
spectively, compared with the SBP associated with 
an excretion of 90 mmol/d. The corresponding DBP 
changes were 5.3 (95% CI, 0.9–9.7), 2.3 (95% CI, 0.5–
4.1), −0.4 (95% CI, −1.5 to 0.7), 0.2 (95% CI, −3.0 to 
−3.3), and 0.8 (95% CI, −4.6 to 6.2). Again, as for the 
analysis based on the BP effects of difference in po-
tassium excretion between the 2 exposures, the pre-
dicted mean SBP and DBP difference on the basis of 
a linear regression function shows an inverse associa-
tion with achieved potassium intake (Figure S1).
When we excluded the studies deemed to have a 
high RoB, the dose- response analysis yielded simi-
lar results of that generated using the entire data set 
(Figures S3 and S4). We repeated the main analysis 
after systematically excluding each study in turn from 
the meta- analysis, and no appreciable variation to the 
overall mean change in BP was noted (Figures S5 and 
S6). Similarly, a sensitivity analysis showing variation 
of the shape across studies identified study- specific 
trends that were generally similar to the overall dose- 
response meta- analysis (Figures S7 and S8).
As reported in Figure  4, dose- response analysis 
according to hypertension status, after removing trials 
performed in “mixed” samples with normal and high 
BP, showed a small decrease in mean BP levels as-
sociated with an increased potassium excretion up to 
20 to 30 mmol/d in both normotensive and hyperten-
sive trials, although in the latter the hypotensive effect 
of potassium was larger and occurred within a larger 
range of higher potassium excretion in supplemented 
participants (up to 90 mmol/d, versus a threshold of 
60  mmol/d in those with no hypertension). For the 
increased BP levels following high amounts of po-
tassium supplementation in participants with hyper-
tension (Figure 5), it was considerably more evident in 
those receiving pharmacological treatment (starting at 
≈60 mmol/d of difference in potassium excretion for 
the supplemented participants) compared with their 
counterparts not taking medications, for whom the BP 
increase started to occur at ≈110 mmol/d of excess 
Figure  2. Dose- response meta- analysis of changes 
in systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) levels (as mm Hg), according to differences 
in potassium excretion between the treatment arms 
(potassium supplemented and control group) at the end of 
the trials.
All studies included (N=32). Spline curve (solid line) with 95% 
confidence limits (long dashed lines).
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potassium excretion. Further investigations to explore 
the effect of different antihypertensive treatment could 
not be performed because the original data did not 
report such stratified analyses by type of medication.
When we performed a conventional forest plot 
analysis, it showed a larger BP decrease following 
potassium supplementation in those with compared 
with those without hypertension (Figure S9). Among 
those with hypertension, potassium supplementa-
tion was on average more effective in lowering BP 
in participants not using antihypertensive medica-
tion compared with those receiving antihyperten-
sive drug treatment (Figure S10). Considering the 
effects of achieved potassium excretion according 
to hypertension status and using 90 mmol/d as the 
reference value (Figure  6), in those in the normal 
BP category, we observed increasing BP levels for 
decreasing potassium exposure below the reference 
value, whereas >90 mmol/d DBP slightly increased 
while this did not occur for SBP. In participants with 
hypertension, the range of 90 to 120 mmol/d was as-
sociated with the lowest BP values, whereas above 
and much more strongly below this range, both SBP 
and DBP increased. In this subgroup, taking or not 
antihypertensive drugs did not appear to be asso-
ciated with major changes in the effect of achieved 
potassium intake on BP levels (Figure 7).
In an analysis stratified by trial design (crossover 
versus parallel), the dose- response analysis showed a 
larger BP decrease in the latter group, but there was 
a higher increase in BP in those receiving the largest 
supplementation, starting at approximately a higher 
excretion of ≈30 mmol/d, in either the overall popula-
tion or those with hypertension (Figures S11 and S12). 
The corresponding forest plot analysis showed a larger 
BP decrease in the crossover studies, in the total sam-
ple and analyses restricted to those with hypertension 
(Figures S13 and S14).
In a dose- response analysis based on pretreatment 
potassium excretion, a larger effect on mean BP dif-
ference was noted in the studies with a urinary potas-
sium <75 mmol/d (Figure S15). Corresponding forest 
plot analyses showed a consistent pattern of a slightly 
higher BP- lowering effect (Figure S16).
Dose- response analyses stratified by increasing level 
of baseline sodium excretion showed that potassium 
supplementation had different effects on BP values, ac-
cording to level of sodium excretion (Figure 8), as de-
picted in the forest plot analysis (Figure S17). Both the 
lowering and the enhancing effects on BP induced by 
potassium supplementation were much weaker in the 
bottom category of sodium intake, <3000 mg/d, par-
ticularly for DBP, whereas in the intermediate category 
of sodium exposure, the threshold from shifting from 
a BP- lowering effect into a BP- enhancing effect was 
≈80  mmol/d of supplemental potassium excretion for 
SBP and 60 mmol/d for DBP. The highest category of 
sodium exposure showed the largest decrease of both 
SBP and DPB, with no evidence of any BP increase, even 
for the highest amount of potassium supplementation.
The modalities of BP measurement associated with 
the largest decreases were when BP was measured in 
the supine and standing positions, and when a manual 
device was used (Figures S18 through S21).
Analyses restricted to trials with a duration of 
≥12 weeks (N=5) are shown in Figure S22. The analy-
sis based on the amount of supplemental potassium 
showed a comparable trend to that observed in the 
entire set of studies, although there was evidence of 
an increased BP- enhancing effect at a lower level of 
excess potassium exposure (ie, for <60  mmol/d of 
potassium difference between intervention and con-
trol arms), whereas this occurred at >60 mmol/d in 
Figure  3. Dose- response meta- analysis of changes in 
systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) levels (as mm Hg), according to achieved potassium 
excretion levels between arms (potassium supplemented 
and control group) at the end of the trials.
All studies included (N=32). Spline curve (solid line) with 95% 
confidence limits (long dashed lines).
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the entire data set (Figure 2). For the analysis based 
on achieved potassium excretion at the end of the 
trial, the results of this subgroup analysis based on 
the longest duration studies showed that 90 mmol/d 
of potassium excretion was the amount associated 
with the most favorable effects on both SBP and 
DPB, with slightly lower estimates compared with the 
entire set of studies (Figure 3). However, in this subset 
of studies, there was no indication of an effect of high 
potassium intake in increasing DBP, which was differ-
ent from what was observed in the entire set of stud-
ies. However, the effect estimates yielded by these 
analyses were statistically imprecise, because of the 
considerably lower number of studies compared with 
the overall trials available.
Funnel plots provided slight evidence of an 
asymmetric distribution for SBP (Figure S23), sug-
gesting the possible occurrence of some publica-
tion bias. However, no such evidence emerged for 
DBP, thus reducing the likelihood of a major pub-
lication bias.
DISCUSSION
The end point most investigated in studies assess-
ing the relationship between potassium exposure and 
human health is BP. This is also the only end point for 
which a large number of experimental human studies 
are available, generally in the form of RCTs with either 
a crossover or a parallel design, this being the study 
design with the strongest level of evidence with ref-
erence to the risk of exposure misclassification and 
confounding.
Despite apparently strong evidence that potassium 
supplementation decreases SBP and DBP,12,14,18,71 the 
exact dose- response of the association has not been 
well established.13 The main reason for this is lack of 
a valid method for assessing dose- response in the 
Figure 4. Dose- response meta- analysis of changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
levels (as mm Hg), according to differences in potassium excretion between the treatment arms at the end of the trials in 
participants with no hypertension (N=5) and with hypertension (N=27).
Spline curve (solid line) with 95% confidence limits (long dashed lines).
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commonly used 2- arm trial design that compares par-
ticipants assigned to potassium supplementation or 
placebo. The biostatistical tools previously available 
for randomized comparison of dose- response effect 
required at least 3 levels of exposure within each trial 
(independent of trial design), to allow calculation of a 
flexible, nonlinear dose- response relationship between 
the exposure of interest and the outcome.19 This limita-
tion has substantially hampered the use of human ex-
perimental studies for the accurate risk assessment of 
potassium supplementation,13 in both the general pop-
ulation and selected subgroups, such as those with 
or at high risk for hypertension. Attempts have been 
made to assess the dose- response relationship be-
tween potassium intake and BP with meta- regression 
models based on the assumption of a “straight- line 
relationship”18 or forest plots based on comparison 
of the highest versus lowest intake levels, which in 
addition compare heterogeneous exposure catego-
ries.14 Unfortunately, none of these approaches allows 
detection and assessment of nonlinear dose- response 
relationships.
By using a new “1- stage” model that allows for in-
clusion of trials with only 2 levels of exposure, as is 
the case for most RCTs, we detected a dose- response 
curve for the BP effects of potassium that was cur-
vilinear across a wide range of treatment differences 
and absolute values of potassium exposure. This may 
have major implications in the risk assessment of po-
tassium supplementation. Our finding of a U- shaped 
relationship between potassium intake and BP was 
somewhat unexpected on the basis of previous clin-
ical trial meta- analyses and assessments. Although 
it confirms previous reports that a minimum dose of 
potassium is necessary for a BP- lowering effect of po-
tassium supplementation, it also suggests that high 
Figure 5. Dose- response meta- analysis of changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
levels (as mm Hg), according to differences in potassium excretion between the treatment arms at the end of the trials in 
subjects with hypertension not taking antihypertensive medications (N=22) and using antihypertensive medications (N=6).
Spline curve (solid line) with 95% confidence limits (long dashed lines).
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doses of potassium may result in a higher level of BP. 
The BP- increasing effect of high potassium exposure 
was observed in both our overall results and the sub-
group analyses of participants with hypertension or a 
normal level of BP, although being stronger in the for-
mer group. The optimal levels of “supplemental” (net 
difference between the 2 arms) and overall (achieved) 
potassium excretion appeared to be 30 and 90 to 
130  mmol/d (1200 and 3500–5100  mg/d), respec-
tively. The corresponding intakes would be higher (ie, 
by using the generally adopted conversion factor of 
1.3,20,21,72–74 ≈1500 mg/d of supplemental potassium 
and an overall intake of 4500–6500 mg/d). However, 
these estimates are based on a heterogeneous pop-
ulation mainly composed by adults with hypertension, 
and therefore not necessarily representing the gen-
eral population. In addition, the estimates are based 
on experience in trials that disproportionally represent 
short- term interventions. Estimates for those with a 
normal level of BP are lower than the aforementioned 
ones (ie, ≈800 mg/d of supplemental potassium and 
4500 mg/d of total potassium intake), and these figures 
are consistent with those yielded by the trials of longer 
duration.
On the basis of the most recent observational ep-
idemiologic literature, a tendency toward a U- shaped 
effect of potassium supplementation on BP was not 
entirely unexpected. In a recent dose- response meta- 
analysis of nonexperimental epidemiologic studies, 
potassium intake appeared to have a dual relation-
ship with the risk of stroke, lower at up to an intake 
of ≈90 mmol (3500 mg)/d, and higher at high levels.21 
This pattern was noted both in BP adjusted and un-
adjusted analyses. In a Chinese community cohort 
study, participants with the lowest and highest intake 
of potassium had an increased risk of hypertension, 
Figure 6. Dose- response meta- analysis of changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
levels (as mm Hg), according to achieved potassium excretion levels between arms at the end of the trials in participants 
with no hypertension (N=5) and with hypertension (N=27).
Spline curve (solid line) with 95% confidence limits (long dashed lines).
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although the increase was much higher in the lat-
ter group,22 thus suggesting that both rather low and 
high intakes of potassium may adversely affect BP 
levels. In the FHS (Framingham Heart Study), those 
with a higher level of serum potassium progressed to 
a higher level of BP or directly to hypertension during 
a 4- year period of follow- up,75 with a J- shaped as-
sociation for women and a U- shaped association 
for men. However, participants with a potassium 
level >6.3 mmol were excluded, and the authors dis-
missed their results as being not “statistically signif-
icant.” In the BRHS (British Regional Heart Study), 
baseline potassium levels were positively associated 
with excess mortality, including increased CVD mor-
tality.76 Results from the National Health and Nutrition 
Examination Survey I also showed higher CVD mor-
tality for participants in the highest category of base-
line serum potassium compared with the intermediate 
one, with the lowest exposure category also showing 
a (slightly) increased risk of death.77 In addition, the 
possibility that chronic hyperkalemia, usually defined 
on the basis of the general population distribution, 
has a U- shaped association with general mortality is 
now being acknowledged24,25 and has been a source 
of some concern, on the basis of the consistent 
results of several cohort studies performed in dis-
eased, high- risk or healthy participants.28,78–82
The public health implications of our findings of a 
U- shaped relationship between potassium excretion 
and BP levels appears to be considerably more im-
portant for a potassium intake that is too “low” rather 
than too “high,” also recognizing that the situation is 
different in clinical practice, where risk associated 
with hyperkaliemia has a different pattern11,24 and 
therapy.83 In fact, potassium intake even in “accul-
turated” populations with an adequate diet tends to 
be lower, and sometimes much lower, than the ad-
equate intake identified and recommended by risk 
Figure 7. Dose- response meta- analysis of changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
levels (as mm Hg), according to achieved potassium excretion levels between arms at the end of the trials in participants 
with hypertension not taking antihypertensive medications (N=22) and using antihypertensive medications (N=6).
Spline curve (solid line) with 95% confidence limits (long dashed lines).
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assessment agencies, public health authorities, and 
professional societies.13,20,84 Therefore, dietary ad-
vice to increase potassium intake is likely to have 
beneficial effects and result in decreased BP levels in 
most populations. On the other hand, some popula-
tions and some selected subgroups and particularly 
some individuals (namely, those with hypertension 
treated with antihypertensive medication), if having a 
high baseline potassium intake, should be advised 
not to exceed the potassium intake levels found to be 
optimal in this meta- analysis. This may also be true 
for individuals with low- to- intermediate sodium in-
take, because our analysis also suggests that those 
with a high sodium intake, as is typical in Western 
populations,85–87 benefit disproportionately from 
potassium supplementation and may also be more 
resistant to the BP increase following administration 
of a high potassium intake, suggesting an interac-
tion between the 2 minerals. In addition, the number 
of studies was not enough to allow us to perform 
more detailed stratified subgroup analyses based 
on presence or absence of hypertension status and 
category of sodium intake, thus preventing us from 
verifying the presence of a possible interaction be-
tween hypertension status and sodium intake. Our 
BP estimates for the BP effect of a high potassium 
intake had wide CIs, making them less certain than 
BP effects at lower intakes of potassium, because of 
the small number of studies with relevant information 
at higher intakes of potassium and the resulting sta-
tistical imprecision of the effect estimate. In addition, 
the results based on achieved potassium excretion 
yielded little evidence of an increase in BP following 
a high potassium intake, further calling for caution 
about the effects of high intake of potassium on BP.
Our results also provide support for the population 
goals for potassium intake recently set by international 
authorities, such as the 90 mmol/d (3500 mg/d) ade-
quate intake adopted by the European Food Safety 
Authority20 and the 87/66 mmol/d (3400–2600 mg/d) 
in men/women, recommended by the US National 
Academy of Medicine,13 based on the outcome of 
observational studies on potassium intake and sev-
eral health end points, such as the risk of stroke for 
the adequate intake set by the European Food Safety 
Authority.
There is strong biological plausibility for a de-
crease in BP with a low intake of potassium, and 
some evidence to support an increase in BP at high 
levels of intake. Several experimental studies in labo-
ratory settings and in animals have identified several 
mechanisms that may explain the BP- lowering effect 
of potassium supplementation.88–90 Conversely, a 
high potassium intake could favor sodium excretion 
Figure 8. Dose-response meta-analysis of changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
levels (as mm Hg), according to studies with baseline sodium (uNa) <3 g/d (N=8), between 3 and 4 g/d (N=17), and ≥4 g/d (N=9).
Spline regression curve (solid line) with 95% confidence limits (long dashed lines).
−10.0
−5.0
0.0
5.0
10.0
SB
P 
di
ffe
re
nc
e 
(m
mH
g)
0 30 60 90 120
Potassium (mmol/day) 
−10.0
−5.0
0.0
5.0
10.0
D
BP
 d
iff
er
en
ce
 (m
mH
g)
0 30 60 90 120
Potassium (mmol/day) 
Baseline uNa <3 g/day
−10.0
−5.0
0.0
5.0
10.0
SB
P 
di
ffe
re
nc
e 
(m
mH
g)
0 30 60 90 120
Potassium (mmol/day) 
−10.0
−5.0
0.0
5.0
10.0
D
BP
 d
iff
er
en
ce
 (m
mH
g)
0 30 60 90 120
Potassium (mmol/day) 
Baseline uNa 3−4 g/day
−10.0
−5.0
0.0
5.0
10.0
SB
P 
di
ffe
re
nc
e 
(m
mH
g)
0 30 60 90 120
Potassium (mmol/day) 
−10.0
−5.0
0.0
5.0
10.0
D
BP
 d
iff
er
en
ce
 (m
mH
g)
0 30 60 90 120
Potassium (mmol/day) 
Baseline uNa ≥4 g/day
Downloaded from http://ahajournals.org by on July 27, 2020
J Am Heart Assoc. 2020;9:e015719. DOI: 10.1161/JAHA.119.015719 14
Filippini et al Potassium and Blood Pressure
and an increase in renin activity and aldosterone 
levels, also dependent on preexisting electrolyte 
balance.11,91–95
Limitations of our meta- analysis and of the under-
lying studies include the fact that most of the trials 
included were of relatively short duration, including 
both the period of supplementation and follow- up 
(median, 4  weeks). Despite exclusion of trials with 
<4  weeks of potassium supplementation and fol-
low- up, which may not reflect the long- term effects 
of habitual potassium intake also attributable to the 
physiological adaptations that occur over time as a 
general response to dietary habits, extrapolation of 
our overall results to long- term effects of potassium 
intake should still be made with caution. However, 
our analysis, restricted to the studies with the longest 
duration, yielded similar results and provides some 
reassurance that our findings may be extrapolated to 
longer periods of intake and therefore be more read-
ily applicable to the general population. Also, our re-
sults, particularly in stratified analyses, were affected 
by statistical imprecision, particularly for the highest 
intakes of potassium and the longest duration of fol-
low- up, because of limited availability of studies in 
these settings.
In conclusion, this is the first meta- analysis to inves-
tigate the effects of potassium supplementation on BP 
levels and with a specific focus on the dose- response 
relationship. We found evidence for a nonlinear asso-
ciation, and for effect modification in those with hyper-
tension, taking antihypertensive medication, or having 
a high sodium intake. Our findings for the effects of 
potassium intake on BP may explain, at least in part, 
the recently observed U- shaped associations between 
serum potassium levels and risk of adverse outcomes 
in observational studies. They also support current 
European and US dietary recommendations for po-
tassium intake and underscore the need to carefully 
address and manage potassium intake within com-
prehensive efforts to prevent CVD in both the general 
population and high- risk subgroups.
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